EMGRAST-M

Main information

  • Trade name:
  • EMGRAST-M VIAL VIAL
  • Dosage:
  • 300MCG(R-HUGMCSF GRANULOCYTE COLONY SIMULATING FACTOR)
  • Pharmaceutical form:
  • VIAL
  • Composition:
  • VIAL
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • EMGRAST-M VIAL VIAL
    India
  • Language:
  • English

Other information

Status

  • Source:
  • Central Drugs Standard Control Organization
  • Last update:
  • 09-08-2016

21-11-2013

Danish Pharmacovigilance Update, 26 September 2013

Danish Pharmacovigilance Update, 26 September 2013

In this issue of Danish Pharmacovigilance Update: Filgrastim (Neupogen) and pegfilgrastim (Neulasta) are associated with risk of capillary leak syndrome.

Danish Medicines Agency

23-2-2018

ZARXIO (Filgrastim-Sndz) Injection, Solution [Sandoz Inc.]

ZARXIO (Filgrastim-Sndz) Injection, Solution [Sandoz Inc.]

Updated Date: Feb 23, 2018 EST

US - DailyMed

20-9-2017

Nivestim (Hospira UK Limited)

Nivestim (Hospira UK Limited)

Nivestim (Active substance: Filgrastim) - Centralised - Yearly update - Commission Decision (2017)6417 of Wed, 20 Sep 2017

Europe -DG Health and Food Safety

28-6-2017

Grastofil (Apotex Europe B.V.)

Grastofil (Apotex Europe B.V.)

Grastofil (Active substance: filgrastim) - Centralised - Yearly update - Commission Decision (2017)4520 of Wed, 28 Jun 2017

Europe -DG Health and Food Safety

23-5-2017

Ratiograstim (ratiopharm GmbH)

Ratiograstim (ratiopharm GmbH)

Ratiograstim (Active substance: filgrastim) - Centralised - Yearly update - Commission Decision (2017)3537 of Tue, 23 May 2017

Europe -DG Health and Food Safety